- Home
- / Hua Medicine
Hua Medicine
Stock Price
$1.8
2024-10-29
Market Capitalization
$1.7 B
2024-10-29
Revenue
¥492.9 M
FY, 2025
Hua Medicine Summary
Company Summary
- Overview
- Hua Medicine (华领医药) is a drug development company. It focuses on therapies for the treatment of diabetes and CNS disorders. The company develops an oral drug for the treatment of type 2 diabetes.
- Type
- Public
- Status
- Active
- Founded
- 2011
- HQ
- Shanghai, CN | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Robert Taylor Nelsen, Chairman
George Lin, EVP & Chief Financial Officer, Executive Director
George Chien Cheng Lin, Executive Director
Operating MetricsView all
Clinics
100
Sep, 2023
Partners
21
Sep, 2023
LocationsView all
5 locations detected
Shanghai, Shanghai Shi HQ
China
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong
Shanghai Shi
China
Xue Lin Lu, Xuhui Qu
Beijing, Beijing
China
Room 7C12, Building 2, Courtyard No.1, Xizhimenwai Street, Xicheng District
Wuhan, Hubei Sheng
China
Rm2504B, 2505B,25th floor, Yuexiu Fortune Center, No.1 Zhongshan Avenue, Qiaokou District
Hong Kong, Hong Kong Island
Hong Kong
Methodist House, 36 Hennessy Rd, Wan Chai
Hua Medicine Financials
Summary Financials
- Revenue (FY, 2025)
- ¥492.9M
- Gross profit (FY, 2025)
- ¥1.6B
- Net income (FY, 2025)
- ¥1.1B
- Cash (FY, 2025)
- ¥1.1B
- EBIT (FY, 2025)
- ¥1.1B
- Enterprise value
- $896.9M